Skip to content
DataLookout
Menu

Bladder Cancer clinical trials

Get alerts when Bladder Cancer trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08

What changed in the last 30 days

96 trials changed in the last 30 days: 1 stopped, 38 with notable changes, 57 with minor changes only.

  1. Minor: 7 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep7 trials
    1. Minor: JK08 · Unresectable Locally Advanced or Metastatic Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Salubris Biotherapeutics IncPhase 1/2 NCT05620134
    2. Minor: NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting NGM Biopharmaceuticals, IncPhase 1 NCT05215574
    3. Minor: GENSA · Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin · Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2022); last known: Recruiting University of ThessalyPhase 3 NCT04947059
    4. Minor: Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Mansoura UniversityNot specified NCT05969964
    5. Minor: LaserEn · SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting University of Kansas Medical CenterNot specified NCT04979156
    6. Minor: Can VI-RADS/ADC Accurately Stage Bladder Cancer?? Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting Mansoura UniversityNot applicable NCT04167631
    7. Minor: IMOPU · Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2018); last known: Not Yet Recruiting Central Hospital, Nancy, FranceNot specified NCT03698721
  2. Notable: At-Home Cancer Directed Therapy Versus in Clinic · Advanced Cancer Primary completion pushed from Jan 1, 2027 to Dec 1, 2027 Mayo ClinicPhase 2 NCT05969860
  3. Notable: TroFuse-055 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) · Bladder Cancer (MK-2870-055) Recruitment opened Merck Sharp & Dohme LLCPhase 3 NCT07829783
  4. Minor: IMvigor011 · Atezolizumab Versus Placebo as Adjuvant Therapy · High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy Trial completed Hoffmann-La RochePhase 3 NCT04660344
  5. Minor: Prophylactic Antibiotics in Cystectomy With Diversion Trial completed University of MinnesotaEarly Phase 1 NCT06190197
  6. Minor: INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) · Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Trial sites expanded: 42 → 60 locations Inhibrx Biosciences, IncPhase 1/2 NCT04198766
  7. Notable: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab · Advanced or Metastatic Malignancy or Other Benign Disease Results posted: Nov 5, 2026 M.D. Anderson Cancer CenterPhase 1 NCT01552434
  8. Minor: TroFuse-027 · Sacituzumab Tirumotecan (MK-2870) · Bladder Cancer (MK-2870-027) Trial completed Merck Sharp & Dohme LLCPhase 1/2 NCT06637423
  9. Minor: Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor Enrollment closed, study ongoing Osijek University HospitalNot specified NCT07165236
  10. Minor: Education and Navigation Support Tool to Improve Participation in Care Coordination · Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers Study completion pushed from Sep 30, 2026 to Sep 25, 2027 Roswell Park Cancer InstituteNot applicable NCT06414317
  11. Notable: CAMPERR · CfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease Primary completion pushed from Mar 2026 to Dec 31, 2026 Adela, IncNot specified NCT05366881
  12. Minor: IMCODE004 · Autogene Cevumeran With Nivolumab Versus Nivolumab Alone · High-risk Muscle-invasive Urothelial Carcinoma (MIUC) Trial sites reduced: 43 → 38 locations Hoffmann-La RochePhase 2 NCT06534983
  13. Minor: Zanidatamab · HER2-expressing Tumors Trial sites expanded: 28 → 42 locations Jazz PharmaceuticalsPhase 2 NCT06695845
  14. Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations Alliance for Clinical Trials in OncologyNot specified NCT05334069
  15. Minor: DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability Trial sites expanded: 23 → 30 locations Alliance for Clinical Trials in OncologyNot applicable NCT07059884
  16. Minor: Vanguard Study: Testing a New Way to Screen for Cancer Interventions modified National Cancer Institute (NCI)Not applicable NCT06995898
  17. Stopped: NeoSTOP-IT · Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer Trial terminated Columbia UniversityPhase 2 NCT06571708
  18. Notable: Performance, Feasibility, and Safety Study for a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours: First-In-Human Trial Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 Chinese University of Hong KongNot applicable NCT06281080
  19. Notable: Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Enrollment increased: 30 → 50 participants Shanxi Province Cancer HospitalPhase 2 NCT07646145
  20. Notable: Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer Enrollment increased: 196 → 350 participants Tianjin Medical University Second HospitalNot applicable NCT07187635
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-27 NCT07898033 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection… dmitry enikeev new Phase 3
2026-10-26 NCT07893509 Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and… Bladder Cancer Advocacy Network new
2026-10-19 NCT07881666 Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical… Hopec Pharma new Phase 1
2026-10-06 NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial… Optheras AS new
2026-10-02 NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) LMU Klinikum new
2026-09-11 NCT07815665 A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in… Summit Therapeutics new Phase 2/3
2026-09-08 NCT07808216 Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk… Tianjin First Central Hospital new Phase 2
2026-08-28 NCT07793318 TR115 in ARID1A-Mutated Advanced Solid Tumors Tarapeutics Science Inc. new Phase 2
2026-08-25 NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in… Janssen-Cilag Farmaceutica Ltda. new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1

Active trials by phase

Early Phase 1
14
Phase 1
111
Phase 1/2
85
Phase 2
216
Phase 2/3
15
Phase 3
86
Phase 4
11
Not charted: 350 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Bladder Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials